Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Read more >>
…Billed as the “premiere venture pitch of the Carolinas,” NEXT gives entrepreneurs a chance to pitch ideas to investors, venture capitalists and community leaders. One of the six finalists is: Zylö Therapeutics — Next-gen, topical drug delivery systems. Read more >>
Silo Pharma, Inc., a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $1,700,000 Small Business Innovation Research (SBIR) grant to advance Zylö’s proprietary nitric-oxide-releasing topical drug candidate into clinical trials. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into a broad-ranging agreement with Amifar Laboratorios Spain to supply Z-pods to further enhance Amifar’s new line of advanced cosmetics. Amifar and Zylö have initiated a product development collaboration beginning with two actives and have plans to expand the list of actives over time. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that Charles E. Hinkle joined its executive team as chief financial officer during the first quarter. Charles began his career as a management consultant at Bain & Company and Bain Capital. Read more >>
Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a Joint Venture with Zylo Therapeutics. This Joint Venture will utilize Zylo’s innovative sustained release topical delivery system that was originally developed at Albert Einstein College of Medicine using Silo Pharma’s expertise in the use of psychedelics. Read more >>
Hoth has a partnership agreement with Zylö Therapeutics Inc., to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Read more >>
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced Jay Blankenship M.D. has joined its executive team as vice president of business development. Read more >>